As of March 31, the EMA had identified 62 cases of CVST worldwide, including 9.2 million doses of AstraZeneca.
Rare but serious question about whether there is a severe blood clot among those who reject AstraZeneca Jab COVID-19 More often than not in the general population and if it happens to them they depend on who gets the vaccines. The European Medicines Agency – which says the vaccine has more benefits than risks – will provide an updated assessment next week.
Did you see
The French Medicines Agency (ANSMM) described the blood clotting of a handful of people who received the AstraZeneca vaccine as “extremely inappropriate.”
“This thrombosis of large veins is abnormally located in the brain and is rarely found in the digestive system,” the agency commented.
It is related to a condition characterized by abnormally low levels of platelets that clot in our tiny blood cells or clot to stop bleeding.
In mid-March, Germany’s drug regulator, the Paul Erlick Institute (PEI), was the first national health authority to identify the largest number of cases related to this rare cerebral blood clot, mostly young and middle-aged women.
According to some experts, the combination of these symptoms indicates the so-called diffuse intravascular coagulation (DIC), where blood clots form throughout the body.
In the extreme case of sepsis, the condition involves both “thrombosis and bleeding,” according to Odil Ln, a member of a scientific organization that advises the French government. COVID-19 Vaccine, AFP reported.
The EMA said last week, “Although the causal link to this vaccine has not been proven, it is possible and further analysis is ongoing.”
The agency is scheduled to hold a meeting on the issue from April 6-7.
Other experts were further classified.
“We need to stop speculating about whether we have this link – all of these events showed these symptoms three to 10 days after the AstraZeneca vaccine was given,” said Paul Andre Hallme, head of the team at Norwegian Television’s Oslo National Hospital. “We could not find any other trigger elements” “
The Norwegian National Drug Agency asked Steiner Madsen, one of its officials, to support the assessment, saying “there is probably a link to this vaccine”.
As part of that, France’s ANSM – pointing to “a very unusual type of thrombosis, with the same clinical profile and onset of the same time” – said there was a “small” risk.
How big is the risk?
As of March 31, the EMA had identified 62 cases of cerebral venous sinus thrombosis (CVST) worldwide – 44 of them in Europe – and AstraZeneca had supplied 9.2 million doses.
EMA chief Immer Cook said in a video conference last week that 14 people had died, although the exact cause of death for this rare form of thrombosis could not be confirmed.
He said the figures are broad or close.
According to the Paul-Erlich Institute, there have been 31 suspected cases of CVST in Germany – nine with 19 low blood platelets.
These cases were spread by injection in only one case per 2.6 million AstraZeneca vaccine dose or 100,000 doses.
Comparative figures in France show 12 cases and four deaths in 1.9 million doses, and five cases in Norway and three deaths in 120,000 doses.
Britain – where AstraZeneca has done more work than any other country – has recorded 30 cases, including seven deaths, with a total dose of 1.1.1 million as of Saturday.
But like all drugs, the risks should always be taken against the benefits
Admiston, a pediatrician at the University of Bristol, commented on the new ban at London’s Science Media Center last week: “We all want to keep drugs 100% safe, but they don’t exist.”
“Right now the biggest risk to our lives and livelihoods is global COVID-19 “Finn added.” Before we can control it, we need to focus on the need to prevent millions more from dying, and this is the only effective way to vaccinate. “
The EMA has consistently echoed this approach.
“Benefits of AstraZeneca Vaccine in Prevention” COVID-19 This has reduced the risk of side effects associated with hospitalization and death.
The cause of the damage?
Most cases of cerebral thrombosis occur in people over the age of 655, but it is impossible to make an age-related decision, as most young people nowadays are vaccinated.
In most cases, what happened to women only reflects the priority given to vaccination in the health sector – mainly women.
The EMA said, “Currently, the review has not identified any specific risk factors for this rare case, such as age, gender or previous treatment history of coagulation.”
Nevertheless, after some countries temporarily suspended AstraZeneca in mid-March, many countries have now suspended the vaccine again.
Germany last week decided to ban it for anyone under the age of 60, although in Canada – in France – the age limit is 5 years. Decreased in Sweden at 655 years of age.
“We don’t just have a vaccine, we have plenty,” wrote Sandra Sisek, a professor of medical virology at Goth University Frankfurt, in the journal Science. “So, it makes sense to me to limit the AstraZeneca vaccine to older people.”
Norway and Sweden have taken more fundamental steps to completely suspend the AstraZeneca vaccine.
At the moment, there are only speculations, although the EMA expects to offer next week which is probably higher.
In a study published March 26, which has not yet been reviewed, German and Austrian researchers point to a known biological process as a possible skin explanation for atypical thrombosis.
The Astragenica vaccine is associated with a thrombosis disorder that is “clinically similar to heparin-induced thrombocytopenia (HIT),” he wrote.
The rare anti-coagulant drug Dragon has a rare and severe reaction to the immune system.
The authors, led by Andreas Grencher from Griffithswald University, proposed a name for what they described as a new syndrome: “Vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).”
Earlier, researchers at Oslo National Hospital suggested that cases could be triggered by a “strong immunity” to the vaccine.
An association of French scientists and physicians “on the side of science” has said that accidental entry into the veins of the upper arm without muscles could lead to such resistance.